NASDAQ · RLAY
Healthcare · Biotechnology
$18.51
Up+$0.50 (+2.70%)
Updated Sep 4, 2026, 12:03 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RLAY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning RLAY.
RLAY research
Company profile and research snapshot.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Barclays | Overweight | — |
| Jul 21, 2026 | Goldman Sachs | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $28 to $29.
Benzinga · Jul 21, 2026
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.
Benzinga · Jul 16, 2026
Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.
SeekingAlpha · Jul 15, 2026
Celcuity wins FDA approval for REVTORPYK in HR+/HER2- breast cancer; outlook tempered by phase 3 data, competition & launch timing. Click for a CELC update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RLAY.
